TSFAE23d:	Subjects With Related Non-serious Treatment-emergent Adverse Events by Preferred Term; Safety Analysis Set (Study jjcs - core)					
 	Active Study Agent 	Active Study Agent 	Active Study Agent 	 	
 	Xanomeline High Dose 	Xanomeline Low Dose 	Combined 	Placebo 	
Preferred Term, n (%) 	N=53 	N=73 	N=126 	N=59 	
Subjects with ≥1 related non-serious AE 	13 (24.5%) 	11 (15.1%) 	24 (19.0%) 	17 (28.8%) 	
 	 	 	 	 	
DIZZINESS 	4 (7.5%) 	1 (1.4%) 	5 (4.0%) 	0 	
FATIGUE 	1 (1.9%) 	2 (2.7%) 	3 (2.4%) 	0 	
SINUS BRADYCARDIA 	2 (3.8%) 	1 (1.4%) 	3 (2.4%) 	0 	
CONTUSION 	1 (1.9%) 	1 (1.4%) 	2 (1.6%) 	0 	
HEADACHE 	2 (3.8%) 	0 	2 (1.6%) 	0 	
SOMNOLENCE 	1 (1.9%) 	1 (1.4%) 	2 (1.6%) 	0 	
VOMITING 	2 (3.8%) 	0 	2 (1.6%) 	0 	
ABDOMINAL PAIN 	0 	1 (1.4%) 	1 (0.8%) 	0 	
ASTHENIA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
CHEST PAIN 	1 (1.9%) 	0 	1 (0.8%) 	0 	
CONJUNCTIVAL HAEMORRHAGE 	0 	1 (1.4%) 	1 (0.8%) 	0 	
COUGH 	0 	1 (1.4%) 	1 (0.8%) 	1 (1.7%) 	
EPISTAXIS 	1 (1.9%) 	0 	1 (0.8%) 	0 	
INCREASED APPETITE 	1 (1.9%) 	0 	1 (0.8%) 	0 	
NASAL CONGESTION 	1 (1.9%) 	0 	1 (0.8%) 	1 (1.7%) 	
NAUSEA 	1 (1.9%) 	0 	1 (0.8%) 	0 	
NIGHTMARE 	1 (1.9%) 	0 	1 (0.8%) 	0 	
PALPITATIONS 	0 	1 (1.4%) 	1 (0.8%) 	0 	
RHINORRHOEA 	0 	1 (1.4%) 	1 (0.8%) 	0 	
SKIN ODOUR ABNORMAL 	1 (1.9%) 	0 	1 (0.8%) 	0 	
VENTRICULAR EXTRASYSTOLES 	0 	1 (1.4%) 	1 (0.8%) 	0 	
ALOPECIA 	0 	0 	0 	1 (1.7%) 	
BLEEDING ANOVULATORY 	0 	0 	0 	1 (1.7%) 	
BUNDLE BRANCH BLOCK RIGHT 	0 	0 	0 	1 (1.7%) 	
CERVICITIS 	0 	0 	0 	1 (1.7%) 	
CONJUNCTIVITIS 	0 	0 	0 	1 (1.7%) 	
DIARRHOEA 	0 	0 	0 	1 (1.7%) 	
DISORIENTATION 	0 	0 	0 	1 (1.7%) 	
DISTURBANCE IN SEXUAL AROUSAL 	0 	0 	0 	1 (1.7%) 	
DYSURIA 	0 	0 	0 	1 (1.7%) 	
ELECTROCARDIOGRAM T WAVE INVERSION 	0 	0 	0 	2 (3.4%) 	
GASTROENTERITIS VIRAL 	0 	0 	0 	1 (1.7%) 	
HYPERTENSION 	0 	0 	0 	1 (1.7%) 	
HYPOTENSION 	0 	0 	0 	1 (1.7%) 	
MYOCARDIAL INFARCTION 	0 	0 	0 	1 (1.7%) 	
OEDEMA PERIPHERAL 	0 	0 	0 	1 (1.7%) 	
PSYCHOMOTOR HYPERACTIVITY 	0 	0 	0 	1 (1.7%) 	
RASH 	0 	0 	0 	1 (1.7%) 	
UPPER RESPIRATORY TRACT INFECTION 	0 	0 	0 	1 (1.7%) 	
URINARY TRACT INFECTION 	0 	0 	0 	1 (1.7%) 	

Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event. 	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: An AE is assessed by the investigator as related. Subjects are counted only once for any given event, regardless of the number of times they actually experienced the event.	
Note: Adverse events are coded using MedDRA version 26.0. 	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.	: Adverse events are coded using MedDRA version 26.